Limits...
Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10202 lung cancer patients.

Gao W, Gulliford M, Higginson IJ - Br. J. Cancer (2011)

Bottom Line: The associated factors were investigated using log-binomial regression.Prescription prevalence of analgesics of all levels showed an increasing trend over the period 2000-2008 (annual increases range: 1.1-1.5%) but a decreasing trend with age (average decrease per group range: -5.8 to -1.8%).However, analgesics, especially at level 3, were relatively under-prescribed to people older than 70 years, warranting further investigation.

View Article: PubMed Central - PubMed

Affiliation: King's College London, School of Medicine, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Bessemer Road, London SE5 9PJ, UK. wei.gao@kcl.ac.uk

ABSTRACT

Background: To describe the prescription patterns of analgesics during the last 3 months of life in lung cancer and to determine the associated factors.

Methods: Data on lung cancer patients (N=10,202) who died during 2000-2008 were extracted from the General Practice Research Database (GPRD). This database records prescriptions of patients received from UK general practices (GP), but not those from non-GP routes. Prescription prevalences were estimated. The associated factors were investigated using log-binomial regression.

Results: The overall prescription prevalences were 50.4% (95% confidence interval (CI): 49.4-51.4%) for level 1 (e.g., paracetamol), 34.1% (95% CI: 33.2-35.0%) for level 2 (weak opioids), and 55.5 % (95% CI: 54.5-56.4%) for level 3 analgesics (strong opioids). Prescription prevalence of analgesics of all levels showed an increasing trend over the period 2000-2008 (annual increases range: 1.1-1.5%) but a decreasing trend with age (average decrease per group range: -5.8 to -1.8%). Patients in the older age groups were less likely to be prescribed level 3 analgesics than those in the younger age groups (PR('90+' vs '<50')=0.55 (95% CI: 0.45-0.67); PR('80-89' vs '<50')=0.73 (95% CI: 0.66-0.79); PR('70-79' vs '<50')=0.84 (95% CI: 0.77-0.90)).

Conclusion: Analgesics have been increasingly prescribed in lung cancer. However, analgesics, especially at level 3, were relatively under-prescribed to people older than 70 years, warranting further investigation.

Show MeSH

Related in: MedlinePlus

Prescription prevalence (95% CI) of level 1, level 2, and level 3 analgesics (according to the WHO analgesic ladder) in patients with lung cancer and proportion of patients without analgesic prescriptions by age groups (n=10 202). Average change per age group: level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003); No prescription: 2.9% (95% CI: 2.2–3.6% P=0.001).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3111163&req=5

fig2: Prescription prevalence (95% CI) of level 1, level 2, and level 3 analgesics (according to the WHO analgesic ladder) in patients with lung cancer and proportion of patients without analgesic prescriptions by age groups (n=10 202). Average change per age group: level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003); No prescription: 2.9% (95% CI: 2.2–3.6% P=0.001).

Mentions: Prescription prevalence for all three levels of analgesics exhibited a linear and significant decreasing trend with increasing age (level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003) (Figure 2). Analgesic prescriptions of level 1 (range: 45.8–55.1%) and level 3 (range: 36.0–65.0%) were both higher in all age groups than level 2 (range: 26.2–39.9%). Prescription prevalence of level 3 drugs were higher than those of level 1 in younger age groups (<70 years) but started dropping from the ‘70–79' age group to lower than level 1 in the ‘90+' group.


Prescription patterns of analgesics in the last 3 months of life: a retrospective analysis of 10202 lung cancer patients.

Gao W, Gulliford M, Higginson IJ - Br. J. Cancer (2011)

Prescription prevalence (95% CI) of level 1, level 2, and level 3 analgesics (according to the WHO analgesic ladder) in patients with lung cancer and proportion of patients without analgesic prescriptions by age groups (n=10 202). Average change per age group: level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003); No prescription: 2.9% (95% CI: 2.2–3.6% P=0.001).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3111163&req=5

fig2: Prescription prevalence (95% CI) of level 1, level 2, and level 3 analgesics (according to the WHO analgesic ladder) in patients with lung cancer and proportion of patients without analgesic prescriptions by age groups (n=10 202). Average change per age group: level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003); No prescription: 2.9% (95% CI: 2.2–3.6% P=0.001).
Mentions: Prescription prevalence for all three levels of analgesics exhibited a linear and significant decreasing trend with increasing age (level 1: −1.8% (95% CI: −2.5 to −1.2%, P=0.005); level 2: −2.6% (95% CI: −3.2 to −1.9%, P=0.002); level 3: −5.8% (95% CI: −7.6 to −4.1%, P=0.003) (Figure 2). Analgesic prescriptions of level 1 (range: 45.8–55.1%) and level 3 (range: 36.0–65.0%) were both higher in all age groups than level 2 (range: 26.2–39.9%). Prescription prevalence of level 3 drugs were higher than those of level 1 in younger age groups (<70 years) but started dropping from the ‘70–79' age group to lower than level 1 in the ‘90+' group.

Bottom Line: The associated factors were investigated using log-binomial regression.Prescription prevalence of analgesics of all levels showed an increasing trend over the period 2000-2008 (annual increases range: 1.1-1.5%) but a decreasing trend with age (average decrease per group range: -5.8 to -1.8%).However, analgesics, especially at level 3, were relatively under-prescribed to people older than 70 years, warranting further investigation.

View Article: PubMed Central - PubMed

Affiliation: King's College London, School of Medicine, Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Bessemer Road, London SE5 9PJ, UK. wei.gao@kcl.ac.uk

ABSTRACT

Background: To describe the prescription patterns of analgesics during the last 3 months of life in lung cancer and to determine the associated factors.

Methods: Data on lung cancer patients (N=10,202) who died during 2000-2008 were extracted from the General Practice Research Database (GPRD). This database records prescriptions of patients received from UK general practices (GP), but not those from non-GP routes. Prescription prevalences were estimated. The associated factors were investigated using log-binomial regression.

Results: The overall prescription prevalences were 50.4% (95% confidence interval (CI): 49.4-51.4%) for level 1 (e.g., paracetamol), 34.1% (95% CI: 33.2-35.0%) for level 2 (weak opioids), and 55.5 % (95% CI: 54.5-56.4%) for level 3 analgesics (strong opioids). Prescription prevalence of analgesics of all levels showed an increasing trend over the period 2000-2008 (annual increases range: 1.1-1.5%) but a decreasing trend with age (average decrease per group range: -5.8 to -1.8%). Patients in the older age groups were less likely to be prescribed level 3 analgesics than those in the younger age groups (PR('90+' vs '<50')=0.55 (95% CI: 0.45-0.67); PR('80-89' vs '<50')=0.73 (95% CI: 0.66-0.79); PR('70-79' vs '<50')=0.84 (95% CI: 0.77-0.90)).

Conclusion: Analgesics have been increasingly prescribed in lung cancer. However, analgesics, especially at level 3, were relatively under-prescribed to people older than 70 years, warranting further investigation.

Show MeSH
Related in: MedlinePlus